Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 15/20 | 0.43 |
| ▸ | JAK3 | P52333 | 15/20 | 0.43 |
| ▸ | JAK1 | P23458 | 9/20 | 0.40 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1781369 | 0.89 | HCAR1 (0.48) | JAK2JAK3JAK1HCAR1TYK2 | |
| SCHEMBL1693604 | 0.88 | HCAR1 (0.50) | JAK2JAK3JAK1HCAR1CCNE2 | |
| SCHEMBL29501865 | 0.88 | HCAR1 (0.50) | JAK2JAK3JAK1HCAR1CCNE2 | |
| SCHEMBL23974060 | 0.86 | JAK2 (0.44) | JAK2JAK3JAK1HCAR1TYK2 | |
| SCHEMBL30379222 | 0.86 | JAK2 (0.44) | JAK2JAK3JAK1HCAR1TYK2 | |
| SCHEMBL20299440 | 0.84 | JAK2 (0.47) | JAK2JAK3JAK1HCAR1TYK2 | |
| SCHEMBL29770995 | 0.84 | JAK2 (0.47) | JAK2JAK3JAK1HCAR1TYK2 | |
| SCHEMBL1693606 | 0.83 | JAK2 (0.59) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL20359146 | 0.83 | JAK2 (0.54) | JAK2JAK3JAK1TYK2PRKDC | |
| SCHEMBL23929312 | 0.83 | JAK2 (0.44) | JAK2JAK3JAK1HCAR1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150355-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2024-05-09 | — | — | US | disclosed |
| US-11884671-B2 | Purinone compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2024-01-30 | — | — | US | disclosed |
| CN-114315834-B | Imidazolone derivatives and their use in medicine | 成都百裕制药股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20230165867-A1 | IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| CN-113121538-B | Furan derivative and application thereof in medicine | 成都百裕制药股份有限公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4137491-A1 | IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE | Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) | 2023-02-22 | — | — | EP | disclosed |
| EP-3807278-B1 | PURINONE DERIVATIVES AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2022-08-31 | — | — | EP | disclosed |
| CN-114315834-A | Imidazolidinone derivatives and their use in medicaments | 成都百裕制药股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2021209055-A1 | IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE | 成都百裕制药股份有限公司 | 2021-10-21 | — | — | WO | disclosed |
| CN-113121538-A | Furan derivative and application thereof in medicine | 成都百裕制药股份有限公司 | 2021-07-16 | — | — | CN | disclosed |
| WO-2021136462-A1 | FURAN DERIVATIVES AND APPLICATION THEREOF IN MEDICINE | 成都百裕制药股份有限公司 | 2021-07-08 | — | — | WO | disclosed |
| US-20210171525-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-10 | — | — | US | disclosed |
| US-20210171525-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-10 | — | — | US | disclosed |
| CN-112236431-A | Purinone compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2021-01-15 | — | — | CN | disclosed |
| WO-2019238929-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171525-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | RECQL, PRPS1, PURB | JAK2 1204/4885JAK3 1390/4885JAK1 978/4885 |
| US-20240150355-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | RECQL, PRPS1, PURB | JAK2 880/4885JAK3 1089/4885JAK1 905/4885 |
| US-20230165867-A1 | IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF | SYMPK, PAICS, CYP2C9 | JAK2 537/4885JAK3 599/4885JAK1 593/4885 |
| US-11884671-B2 | Purinone compounds and their use in treating cancer | RECQL, PRPS1, PURB | JAK2 1204/4885JAK3 1390/4885JAK1 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.